An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologic confirmation of adenocarcinoma of the prostate

- Evidence of stage IV disease on previous bone, CT, and/or MRI scan

- Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone
(GnRH) analogue or bilateral orchiectomy

- Mandatory plasma and fresh or archival tumor tissue must be submitted

Exclusion Criteria:

- Prior malignancy active within the previous 3 years except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the breast

- Participants with active brain metastases

- Participants must have recovered from the effects of major surgery requiring general
anesthesia or significant traumatic injury at least 14 days before treatment arm
assignment

Other protocol defined inclusion/exclusion criteria could apply